Bartlett & CO. Wealth Management LLC Trims Stock Position in Novo Nordisk A/S (NYSE:NVO)

Bartlett & CO. Wealth Management LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 40.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,886 shares of the company's stock after selling 28,859 shares during the quarter. Bartlett & CO. Wealth Management LLC's holdings in Novo Nordisk A/S were worth $3,027,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of NVO. Revolve Wealth Partners LLC raised its position in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after buying an additional 200 shares during the last quarter. IFP Advisors Inc raised its position in Novo Nordisk A/S by 5.4% during the 4th quarter. IFP Advisors Inc now owns 11,558 shares of the company's stock worth $994,000 after buying an additional 594 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in Novo Nordisk A/S during the 4th quarter worth approximately $13,282,000. Sentinel Trust Co. LBA raised its position in Novo Nordisk A/S by 0.4% during the 4th quarter. Sentinel Trust Co. LBA now owns 44,366 shares of the company's stock worth $3,816,000 after buying an additional 194 shares during the last quarter. Finally, Illumine Investment Management LLC purchased a new position in Novo Nordisk A/S during the 4th quarter worth approximately $242,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.2%

Shares of NVO traded up $0.80 during trading on Friday, reaching $68.50. 5,624,379 shares of the company traded hands, compared to its average volume of 7,239,527. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $145.99. The stock has a market cap of $305.85 billion, a PE ratio of 20.27, a price-to-earnings-growth ratio of 1.22 and a beta of 0.66. The stock has a 50-day simple moving average of $69.11 and a 200-day simple moving average of $77.04. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NVO. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Finally, Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.